Uveitis - Epidemiology Forecast-2028

September 2019 | 100 pages | ID: U36CB13B66BEN
DelveInsight

Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight’s ‘Uveitis - Epidemiology Forecast-2028’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology trends of Uveitis in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2028

Uveitis - Disease Understanding

The DelveInsight Uveitis report gives a thorough understanding of the Uveitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends.

Prevent Blindness Organization defines Uveitis as, a term for inflammation of the eye. It is an inflammation of the uvea, the pigmented layer that lies between the inner retina and the outer fibrous layer composed of the sclera and cornea. It is caused by inflammatory responses inside the eye that can be caused due to tissue damage, germs, or toxins which lead swelling, redness, heat, and destroys tissues as certain white blood cells rush to the affected part.

Uveitis is classified anatomically as anterior, intermediate, posterior, or diffuse. Anterior uveitis typically refers to inflammation of the iris and anterior chamber; intermediate uveitis refers to inflammation of the ciliary body and vitreous humor (the jellylike filling in the anterior portion of the eye); and posterior uveitis refers to inflammation of the retina, choroid, or the optic disk (where the optic nerve enters the retina). Diffuse uveitis (Panuveitis) implies inflammation of the entire uveals tract. Symptoms of acute forms of uveitis include ocular pain, photophobia, lacrimation, and redness. Uveitis is most often idiopathic but has been associated with traumatic, inflammatory, and infectious processes. Patients may present with concurrent systemic symptoms or infectious diseases to suggest an etiology affecting more than just the eye. Idiopathic cases of uveitis account for 48 to 70% of uveitis cases.

Uveitis – Epidemiology

The Uveitis epidemiology division provide insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalence of Uveitis in 7MM, Total Diagnosed Prevalence of Uveitis in 7MM, Gender-specific Diagnosed Prevalence of Uveitis, Age-specific Diagnosed Prevalence of Uveitis, Type Specific Diagnosed Prevalence of Uveitis, Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location, and Grade-specific Diagnosed Prevalence of Uveitis) scenario of Uveitis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2028.

According to DelveInsight’s estimates, total prevalent population of Uveitis in the seven major markets ranges from approximately 897,400 in 2017 to XXX cases in 2028.

The United Sates accounted for the maximum number of Uveitis patients with approximately 357,700 cases in 2017 followed by Japan with approximately 166,470 cases. Among the European countries, Germany had the maximum prevalent population of Uveitis with approximately 93,200 cases followed by France, which had a prevalent population of approximately 77,300 in 2017.

The United States also accounted for the maximum prevalent cases of NIU (Non-Infectious Uveitis) with around 277,570 prevalent cases in 2017, followed by Japan (approximately 94,000) and Germany (around 57,200).

In 2017, Acute Anterior Uveitis was accounted for 43.00% of the total cases of Uveitis in the United States. Acute anterior noninfectious uveitis includes Grade 0 and 1, and accounts for approximately 93,180 cases in 2017. While, in same year, around 123,500 cases of chronic anterior noninfectious uveitis out of which Grade 2 has approximately 79,800 cases; Grade 3 has approximately 29,700; and Grade 4 has around 13,800 cases respectively. Furthermore, these cases are expected to increase at a significant rate during forecast period.

Uveitis Report Insights

• The report covers a descriptive overview of the Uveitis, explaining its causes, risk factors, pathophysiology and diagnosis.
• Comprehensive insight has been provided into the epidemiology Uveitis in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• Assesses growth opportunities in the 7MM countries with respect to the patient population.

Uveitis Report Key Strengths

• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Total Patient Pool with Uveitis
• Diagnosed Patient Pool of Uveitis
• Gender Specific Patient Pool of Uveitis
• Age Specific Patient Pool of Uveitis
• Type Specific Patient Pool of Uveitis
• Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
• Grade Specific Patient Pool of Uveitis

Uveitis Report Assessment

• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles

Key Benefits

• Key assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by Severity

Contents

1. KEY INSIGHT

2. UVEITIS MARKET OVERVIEW AT A GLANCE

2.1. Market Share (%) Distribution of Uveitis in 2017
2.2. Market Share (%) Distribution of Uveitis in 2028

3. DISEASE BACKGROUND AND OVERVIEW: UVEITIS

3.1. Introduction
3.2. Classification of Uveitis
3.3. International Uveitis Study Group (IUSG) Clinical Classification of Uveitis
3.4. The Standardization of Uveitis Nomenclature (SUN) Working Group
3.5. Symptoms of Uveitis
3.6. Pathophysiology
3.7. Etiology of Uveitis
3.8. Diagnosis of Uveitis
  3.8.1. American Academy of Family Physicians

4. EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Key Findings
4.2. Prevalent Population of Uveitis in the 7MM
4.3. Diagnosed Prevalent Population of Uveitis in the 7MM
4.4. Type Specific Diagnosed Prevalent Population of Uveitis in the 7MM

5. UNITED STATES-EPIDEMIOLOGY OF UVEITIS

5.1. Assumptions and Rationale
5.2. Total Prevalent Population of Uveitis in the United States
5.3. Diagnosed Prevalent Population of Uveitis in the United States
5.4. Gender-Specific Diagnosed Prevalent Population of Uveitis in United States
5.5. Age-Specific Diagnosed Prevalent Population of Uveitis in United States
5.6. Type Specific Diagnosed Prevalent Population of Uveitis in United States
5.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
  5.7.1. Diagnosed prevalent cases of Anterior noninfectious Uveitis (aNIU) in the United States
  5.7.2. Diagnosed prevalent cases of Nonanterior NIU (Posterior Segment) or NIPU in the United States
5.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the United States

6. EU-5 EPIDEMIOLOGY OF UVEITIS

6.1. Germany
  6.1.1. Assumptions and Rationale
  6.1.2. Prevalent Population of Uveitis in Germany
  6.1.3. Diagnosed Prevalent Population of Uveitis in Germany
  6.1.4. Gender Specific Diagnosed Prevalence of Uveitis in Germany
  6.1.5. Age Group Specific Diagnosed Prevalence of Uveitis in Germany
  6.1.6. Type Specific Diagnosed Prevalence of Uveitis in Germany
  6.1.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
  6.1.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Germany
6.2. France
  6.2.1. Assumptions and Rationale
  6.2.2. Prevalent Population of Uveitis in France
  6.2.3. Diagnosed Prevalent Population of Uveitis in France
  6.2.4. Gender Specific Diagnosed Prevalence of Uveitis in France
  6.2.5. Age Specific Diagnosed Prevalence of Uveitis in France
  6.2.6. Type Specific Diagnosed Prevalence of Uveitis in France
  6.2.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
  6.2.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in France
6.3. Italy
  6.3.1. Assumptions and Rationale
  6.3.2. Prevalent Population of Uveitis in the Italy
  6.3.3. Diagnosed Prevalent Population of Uveitis in Italy
  6.3.4. Gender Specific Diagnosed Prevalence of Uveitis in Italy
  6.3.5. Age Specific Diagnosed Prevalence of Uveitis in Italy
  6.3.6. Type Specific Diagnosed Prevalence of Uveitis in Italy
  6.3.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
  6.3.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Italy
6.4. Spain
  6.4.1. Assumptions and Rationale
  6.4.2. Prevalent Population of Uveitis in the Spain
  6.4.3. Diagnosed Prevalent Population of Uveitis in Spain
  6.4.4. Gender Specific Diagnosed Prevalence population of Uveitis in Spain
  6.4.5. Age Specific Diagnosed Prevalence of Uveitis in Spain
  6.4.6. Type Specific Diagnosed Prevalence of Uveitis in Spain
  6.4.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Spain
  6.4.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Spain
6.5. United Kingdom
  6.5.1. Assumptions and Rationale
  6.5.2. Prevalent Population of Uveitis in the UK
  6.5.3. Diagnosed Prevalent Population of Uveitis in United Kingdom
  6.5.4. Gender Specific Diagnosed Prevalence of Uveitis in UK
  6.5.5. Age Specific Diagnosed Prevalence of Uveitis in UK
  6.5.6. Type Specific Diagnosed Prevalence of Uveitis in UK
  6.5.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the UK
  6.5.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the UK

7. JAPAN

7.1. Assumptions and Rationale
7.2. Prevalent Population of Uveitis in the Japan
7.3. Diagnosed Prevalent Population of Uveitis in the Japan
7.4. Gender Specific Prevalence of Uveitis in Japan
7.5. Age Specific Prevalence of Uveitis in Japan
7.6. Type Specific Prevalence of Uveitis in Japan
7.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Japan
7.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Japan

8. APPENDIX

9. REPORT METHODOLOGY

9.1. Sources Used

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

List Of Tables

LIST OF TABLES

Table 1 IUSG Clinical Classification of Uveitis
Table 2 The SUN Working Group Anatomic Classification of Uveitis
Table 3 The SUN Working Group Descriptors of Uveitis
Table 4 The SUN Working Group Grading Scheme for Anterior Chamber Cells
Table 5 The SUN Working Group Grading Scheme for Anterior Chamber Cells
Table 6 KEY RECOMMENDATIONS FOR PRACTICE
Table 7 Region-Wise Prevalent Population of Uveitis (2017–2028)
Table 8 Diagnosed Prevalent Population of Uveitis (2017–2028)
Table 9 Type Specific Diagnosed Prevalent Population of Uveitis in the 7MM (2017–2028)
Table 10 Total Prevalent Population of Uveitis in US (2017–2028)
Table 11 Total Diagnosed Prevalent Population of Uveitis in US (2017–2028)
Table 12 Gender Specific Diagnosed Prevalent Population of Uveitis in the US (2017–2028)
Table 13 Age-Specific Diagnosed Prevalent Population of Uveitis in the US (2017–2028)
Table 14 Type-Specific Diagnosed Prevalent Population of Uveitis in US (2017–2028)
Table 15 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the United States (2017–2028)
Table 16 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the United States (2017–2028)
Table 17 Prevalent Population of Uveitis in Germany (2017–2028)
Table 18 Diagnosed Prevalent Population of Uveitis in Germany (2017–2028)
Table 19 Gender Specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2028)
Table 20 Age Specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2028)
Table 21 Type Specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2028)
Table 22 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Germany (2017–2028)
Table 23 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Germany (2017–2028)
Table 24 Prevalent Population of Uveitis in France (2017–2028)
Table 25 Diagnosed Prevalent Population of Uveitis in France (2017–2028)
Table 26 Gender Specific Diagnosed Prevalent Population of Uveitis in France (2017–2028)
Table 27 Age Specific Diagnosed Prevalent Population of Uveitis in France (2017–2028)
Table 28 Type Specific Diagnosed Prevalent Population of Uveitis in France (2017–2028)
Table 29 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in France (2017–2028)
Table 30 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in France (2017–2028)
Table 31 Prevalent Population of Uveitis in Italy (2017–2028)
Table 32 Diagnosed Prevalent Population of Uveitis in Italy (2017–2028)
Table 33 Gender Specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2028)
Table 34 Age Specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2028)
Table 35 Type Specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2028)
Table 36 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Italy (2017–2028)
Table 37 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Italy (2017–2028)
Table 38 Prevalent Population of Uveitis in Spain (2017–2028)
Table 39 Diagnosed Prevalent Population of Uveitis in Spain (2017–2028)
Table 40 Gender Specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2028)
Table 41 Age Specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2028)
Table 42 Type Specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2028)
Table 43 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Spain (2017–2028)
Table 44 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Spain (2017–2028)
Table 45 Prevalent Population of Uveitis in UK (2017–2028)
Table 46 Diagnosed Prevalent Population of Uveitis in UK (2017–2028)
Table 47 Gender Specific Diagnosed Prevalent Population of Uveitis in UK (2017–2028)
Table 48 Age Specific Prevalent Population of Uveitis in UK (2017–2028)
Table 49 Type Specific Diagnosed Prevalent Population of Uveitis in UK (2017–2028)
Table 50 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in UK (2017–2028)
Table 51 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in UK (2017–2028)
Table 52 Prevalent Population of Uveitis in Japan (2017–2028)
Table 53 Diagnosed Prevalent Population of Uveitis in Japan (2017–2028)
Table 54 Gender Specific Prevalent Population of Uveitis in Japan (2017–2028)
Table 55 Age Specific Prevalent Population of Uveitis in Japan (2017–2028)
Table 56 Type Specific Prevalent Population of Uveitis in Japan (2017–2028)
Table 57 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Japan (2017–2028)
Table 58 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Japan (2017–2028)

List Of Figures

LIST OF FIGURES

Figure 1 Structure of Eye
Figure 2 Types of Uveitis and Affected area
Figure 3 Classification of Uveitis
Figure 4 Types of Uveitis are based on the different parts of eye. Below are the four types
Figure 5 Symptoms of Uveitis
Figure 6 Pathogenetic mechanism of Uveitis
Figure 7 Mechanism of antigen processing and presentation.
Figure 8 Autoimmune conditions that cause uveitis
Figure 9 Causes of Uveitis
Figure 10 Diagnosis algorithm for Uveitis
Figure 11 Prevalent Population of Uveitis in the 7MM (2017–2028)
Figure 12 Diagnosed Prevalent Population of Uveitis in the 7MM (2017–2028)
Figure 13 Type Specific Diagnosed Prevalent Population of Uveitis in the 7MM (2017–2028)
Figure 14 Total Prevalent Population of Uveitis in United States (2017–2028)
Figure 15 Diagnosed Prevalent Population of Uveitis in United States (2017–2028)
Figure 16 Gender-Specific Diagnosed Prevalent Population of Uveitis in United States (2017–2028)
Figure 17 Age-Specific Diagnosed Prevalent Population of Uveitis in the United States (2017–2028)
Figure 18 Type Specific Diagnosed Prevalent Population of Uveitis in the US (2017–2028)
Figure 19 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the United States (2017–2028)
Figure 20 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the United States (2017–2028)
Figure 21 Prevalent Population of Uveitis in Germany (2017–2028)
Figure 22 Diagnosed Prevalent Population of Uveitis in Germany (2017–2028)
Figure 23 Gender Specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2028)
Figure 24 Age Specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2028)
Figure 25 Type Specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2028)
Figure 26 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Germany (2017–2028)
Figure 27 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Germany 2017–2028)
Figure 28 Prevalent Population of Uveitis in France (2017–2028)
Figure 29 Diagnosed Prevalent Population of Uveitis in France (2017–2028)
Figure 30 Gender Specific Diagnosed Prevalent Population of Uveitis in France (2017–2028)
Figure 31 Age Specific Diagnosed Prevalent Population of Uveitis in France (2017–2028)
Figure 32 Type Specific Diagnosed Prevalent Population of Uveitis in France (2017–2028)
Figure 33 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in France (2017–2028)
Figure 34 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in France (2017–2028)
Figure 35 Prevalent Population of Uveitis in Italy (2017–2028)
Figure 36 Diagnosed Prevalent Population of Uveitis in Italy (2017–2028)
Figure 37 Gender Specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2028)
Figure 38 Age Specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2028)
Figure 39 Type Specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2028)
Figure 40 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Italy (2017–2028)
Figure 41 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Italy (2017–2028)
Figure 42 Prevalent Population of Uveitis & Non-Infectious Uveitis (NIU) in Spain (2017–2028)
Figure 43 Diagnosed Prevalent Population of Uveitis in Spain (2017–2028)
Figure 44 Gender Specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2028)
Figure 45 Age Specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2028)
Figure 46 Type Specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2028)
Figure 47 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Spain (2017–2028)
Figure 48 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Spain (2017–2028)
Figure 49 Prevalent Population of Uveitis in UK (2017–2028)
Figure 50 Diagnosed Prevalent Population of Uveitis in UK (2017–2028)
Figure 51 Gender Specific Diagnosed Prevalent Population of Uveitis in UK (2017–2028)
Figure 52 Age Specific Diagnosed Prevalent Population of Uveitis in UK (2017–2028)
Figure 53 Type Specific Diagnosed Prevalent Population of Uveitis in the UK (2017–2028)
Figure 54 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the UK (2017–2028)
Figure 55 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the UK (2017–2028)
Figure 56 Prevalent Population of Uveitis in Japan (2017–2028)
Figure 57 Diagnosed Prevalent Population of Uveitis in Japan (2017–2028)
Figure 58 Gender Specific Prevalent Population of Uveitis in Japan (2017–2028)
Figure 59 Age Specific Prevalent Population of Uveitis in JAPAN (2017–2028)
Figure 60 Type Specific Prevalent Population of Uveitis in JAPAN (2017–2028)
Figure 61 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Japan (2017-2028)
Figure 62 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Japan (2017–2028)